Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Drop in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totaling 13,598 shares, a decline of 60.8% from the September 15th total of 34,666 shares. Based on an average daily volume of 32,535 shares, the short-interest ratio is presently 0.4 days. Approximately 1.0% of the company’s stock are short sold.

Aspire Biopharma Trading Up 7.8%

NASDAQ ASBP traded up $0.61 during trading hours on Tuesday, reaching $8.39. 20,163 shares of the company traded hands, compared to its average volume of 283,012. Aspire Biopharma has a 12 month low of $3.31 and a 12 month high of $562.92. The stock has a market capitalization of $11.77 million, a PE ratio of -0.12 and a beta of 0.17. The company has a 50 day moving average of $8.30 and a two-hundred day moving average of $9.68.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma, Inc is a biotechnology company focused on developing rapid drug-delivery technologies and pharmaceutical products. The company’s platform is designed to administer medications through the sublingual and buccal tissues of the mouth, with the goal of enabling faster absorption than conventional oral tablets.

Aspire Biopharma’s lead product candidate is an orally delivered, fast-acting aspirin formulation intended for potential use in cardiovascular emergencies and other situations in which rapid aspirin administration may be beneficial.